My analysis says prolly 90 died in the trial out of 394... Dont know how many in which arm of the trial ..But EIND's patients in critical or severe had about a 16% death rate with LL treatment vs other multiple choices of care including, which most got in the trial as well .So i would say pretty accurate that 16%. ..I like the cd12 trial success chances...This is direct analysis unlike yours which is all over the place..
CD12 cannot be compared to general statistics. Patients that make a decision to participate in a clinical trial are typically in worse shape than patients that are responding to SOC treatment. So it's safe to say patients in CD12 are the sickest of the sick. That's why it's a trial, to compare Leronlimab to placebo patients not general statistics from patients that are not participating in the trial. No data from the trial has been released so this is only your personal opinion. Your analysis is wrong. Not only wrong you are in a completely different ball park. CD12 will be approved.
Market Data 
Markets 
AI
